<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medsovet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский Совет</journal-title><trans-title-group xml:lang="en"><trans-title>Meditsinskiy sovet = Medical Council</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2079-701X</issn><issn pub-type="epub">2658-5790</issn><publisher><publisher-name>REMEDIUM GROUP Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21518/2079-701X-2013-5-6-83-85</article-id><article-id custom-type="elpub" pub-id-type="custom">medsovet-3614</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОНКОЛОГИЯ И ОНКОГЕМАТОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ONCOLOGY AND ONCOHEMATOLOGY</subject></subj-group></article-categories><title-group><article-title>Таксаны как первая и вторая линии химиотерапии метастатического рака предстательной железы</article-title><trans-title-group xml:lang="en"><trans-title></trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мишугин</surname><given-names>С. В.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н., </p><p>Москва</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Скворцова</surname><given-names>Т. Н.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Москва</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Русаков</surname><given-names>И. Г.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., профессор, </p><p>Москва</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff xml:lang="ru" id="aff-1"><institution>ГБУЗ ГКБ №57</institution><country>Russian Federation</country></aff><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>26</day><month>09</month><year>2019</year></pub-date><volume>0</volume><issue>5-6</issue><fpage>83</fpage><lpage>85</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Мишугин С.В., Скворцова Т.Н., Русаков И.Г., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Мишугин С.В., Скворцова Т.Н., Русаков И.Г.</copyright-holder><copyright-holder xml:lang="en">Мишугин С.В., Скворцова Т.Н., Русаков И.Г.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-sovet.pro/jour/article/view/3614">https://www.med-sovet.pro/jour/article/view/3614</self-uri><abstract><p>Рак предстательной железы (РПЖ) является одним из наиболее распространенных онкологических заболеваний у мужчин. Ежегодно в мире регистрируют более 600 тыс. новых случаев, а в ряде стран, где его встречаемость наиболее высока (США, Канада, Северная Европа), он вышел на первое место в структуре онкологической заболеваемости мужского населения [1, 2].</p></abstract><kwd-group xml:lang="ru"><kwd>онкология</kwd><kwd>рак предстательной железы</kwd><kwd>гормональная терапия</kwd><kwd>таксаны</kwd><kwd>кабазитаксел</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Jemal A., Siegel R., Ward E. et al. Cancer statistics. 2008. CA Cancer // J. Clin. 2008. № 58 (2). Р. 71–96.</mixed-citation><mixed-citation xml:lang="en">Jemal A., Siegel R., Ward E. et al. Cancer statistics. 2008. CA Cancer // J. Clin. 2008. № 58 (2). Р. 71–96.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">http://www.seer.cancer.gov/statfacts/html/prost.html (по данным 12 апреля 2011 г.).</mixed-citation><mixed-citation xml:lang="en">http://www.seer.cancer.gov/statfacts/html/prost.html (по данным 12 апреля 2011 г.).</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Злокачественные новообразования в России в 2011 году // под ред. В. И. Чиссова, В. В. Старинского, Г. В. Петровой. 2013.</mixed-citation><mixed-citation xml:lang="en">Злокачественные новообразования в России в 2011 году // под ред. В. И. Чиссова, В. В. Старинского, Г. В. Петровой. 2013.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Prostate Cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up//Ann. Oncol. 2012.</mixed-citation><mixed-citation xml:lang="en">Prostate Cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up//Ann. Oncol. 2012.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Алексеев Б. Я., Андрианов А. Н. Возможности и механизмы действия гормональной терапии у больных кастрационнорезистентным раком предстательной железы // Онкоурология. 2113. №1. С. 34–43.</mixed-citation><mixed-citation xml:lang="en">Алексеев Б. Я., Андрианов А. Н. Возможности и механизмы действия гормональной терапии у больных кастрационнорезистентным раком предстательной железы // Онкоурология. 2113. №1. С. 34–43.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Kish J., Bukkapatnam R. et al. The treatment challenge of hormone-refractory prostate cancer // Cancer Care. 2001. №8 (6). Р. 487–495.</mixed-citation><mixed-citation xml:lang="en">Kish J., Bukkapatnam R. et al. The treatment challenge of hormone-refractory prostate cancer // Cancer Care. 2001. №8 (6). Р. 487–495.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Harris K. A., Reese D. M. Treatment options in hormone-refractory prostate cancer: current and future approaches // Drugs. 2001. №61. Р. 2177–2192.</mixed-citation><mixed-citation xml:lang="en">Harris K. A., Reese D. M. Treatment options in hormone-refractory prostate cancer: current and future approaches // Drugs. 2001. №61. Р. 2177–2192.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Kantoff P. W., Halabi S., Conaway M. et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study // J. Clin. Oncol. 1999. №17. Р. 2506–2513.</mixed-citation><mixed-citation xml:lang="en">Kantoff P. W., Halabi S., Conaway M. et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study // J. Clin. Oncol. 1999. №17. Р. 2506–2513.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Berthold D. R. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study // J. Clin. Oncol. 2008. №10. 26 (2). Р. 242–245.</mixed-citation><mixed-citation xml:lang="en">Berthold D. R. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study // J. Clin. Oncol. 2008. №10. 26 (2). Р. 242–245.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Tannok I. F., de Wit R., Berry W. R. et al. Docetaxel plus prednisolone for advanced prostate cancer // N. Engl. J. Med. 2004. №351. Р. 1502–1512.</mixed-citation><mixed-citation xml:lang="en">Tannok I. F., de Wit R., Berry W. R. et al. Docetaxel plus prednisolone for advanced prostate cancer // N. Engl. J. Med. 2004. №351. Р. 1502–1512.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Карякин О. Б. [и др.] Российский опыт применения Таксотера в терапии метастатического гормонорефрактерного рака предстательной железы: результаты описательного исследования TANDEM // Онкоурология. 2010. №4. С. 61–64.</mixed-citation><mixed-citation xml:lang="en">Карякин О. Б. [и др.] Российский опыт применения Таксотера в терапии метастатического гормонорефрактерного рака предстательной железы: результаты описательного исследования TANDEM // Онкоурология. 2010. №4. С. 61–64.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Petrylak D. P. et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer // N. Engl. J. Med. 2004.№7; 351 (15). Р. 1513–1520.</mixed-citation><mixed-citation xml:lang="en">Petrylak D. P. et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer // N. Engl. J. Med. 2004.№7; 351 (15). Р. 1513–1520.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Paller Channing J., Antonarakis Emmanuel S. Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer // Drug. Des Devel. Ther. 2011. №5. Р. 117–124.</mixed-citation><mixed-citation xml:lang="en">Paller Channing J., Antonarakis Emmanuel S. Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer // Drug. Des Devel. Ther. 2011. №5. Р. 117–124.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Wilkes G. Cabazitaxel, a taxane for men with hormone-refractory metastatic prostate cancer//Oncology (Williston Park). 2010. №24 (Suppl. 10). Р. 46–48.</mixed-citation><mixed-citation xml:lang="en">Wilkes G. Cabazitaxel, a taxane for men with hormone-refractory metastatic prostate cancer//Oncology (Williston Park). 2010. №24 (Suppl. 10). Р. 46–48.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">De Bono J. S., Oudard S., Ozguroglu M. et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial // Lancet. 2010. №376 (9747). Р. 1147–1154.</mixed-citation><mixed-citation xml:lang="en">De Bono J. S., Oudard S., Ozguroglu M. et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial // Lancet. 2010. №376 (9747). Р. 1147–1154.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Heidenreich A., Scholzb H., Rogenhoferc S. et al. Cabazitaxel Plus Prednisone for Metastatic Castration-resistant Prostate Cancer Progressing After Docetaxel: Results from the German Compassionate-use Programme // European Urology. June 2013. Vol. 63. Is. 6. Р. 977–982.</mixed-citation><mixed-citation xml:lang="en">Heidenreich A., Scholzb H., Rogenhoferc S. et al. Cabazitaxel Plus Prednisone for Metastatic Castration-resistant Prostate Cancer Progressing After Docetaxel: Results from the German Compassionate-use Programme // European Urology. June 2013. Vol. 63. Is. 6. Р. 977–982.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
